[Stock in Focus] SC Engineering Surges as Subsidiary Cellontech Runs Plants at Full Capacity Amid Order Backlog

SC Engineering is showing strong performance. This is believed to be influenced by news that its wholly owned subsidiary, Cellontech, is about to secure new production capacity (CAPA) due to supply shortages.

As of 9:14 a.m. on June 25, SC Engineering was trading at 1,372 won, up 93 won (7.27%) from the previous trading day.

Cellontech is a company specializing in biocollagen medical devices. The Seongsu plant is already operating at 100% capacity, and the company is preparing a new plant in Namyangju with a total floor area of 16,670 square meters. Cellontech has already secured 125 billion won in minimum order quantities (MOQ) from companies such as China's Sihuan Pharmaceutical, and also plans to target new markets in Latin America and other regions.

Based on its unrivaled domestic biocollagen technology, Cellontech develops and sells a variety of medical devices, including the intra-articular injection 'Cartizol', the tissue substitute 'Regenseal', and the facial filler 'Therafill'. The company has established joint marketing systems with partners such as LG Chem, Kolon Pharmaceutical, and DongKook Pharmaceutical. Thanks to the performance of its main products, Cellontech's revenue, which stood at 7.2 billion won in 2021, grew significantly to 18.2 billion won last year.